---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-032004"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-04-04T23:59:59+00:00"
generated_at: "2026-05-23T21:10:04.709230+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharma announces 1-for-20 reverse ADS split to regain Nasdaq compliance

## Summary
- ADS ratio changed from 1:1 to 1:20 (one ADS now represents 20 ordinary shares) effective April 8, 2025.
- Reverse split automatically converts every 20 existing ADSs into 1 new ADS; ordinary shares unchanged.
- New CUSIP number for ADSs is 74907L409; ticker QNRX remains on Nasdaq Capital Market.
- Objective is to increase ADS per-share price above $1.00 minimum bid to avoid delisting.
- Company cannot guarantee that the ratio change will achieve or sustain Nasdaq compliance.

## SEC filing metadata
- accession: 0001104659-25-032004
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-04-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925032004/0001104659-25-032004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925032004/tm2511401d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-032004
- JSON: https://secwatch.observer/filing/0001104659-25-032004.json
- Plain text: https://secwatch.observer/filing/0001104659-25-032004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.